Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Sangamo Biosciences, Inc. (NasdaqNM:SGMO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
501 Canal Boulevard, Suite A100
Richmond, CA 94804
Phone: (510) 970-6000
Fax: (510) 236-8951
Email: info@sangamo.com
Employees (last reported count): 66
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Services
 ·Industry: Business Services
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 73%
·Over the last 6 months:
 · 4 insider buys; 1,000  shares
 · 4 insider sells; 35.0K shares
  (0.2% of insider shares)
·Institutional: 28% (104% of float)
(69 institutions)
·Net Inst. Buying: 914.0K shares (+12.80%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Sangamo Biosciences, Inc. is engaged in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific deoxyribonucleic acid (DNA) sequences. The Company's Universal Gene Recognition platform is a proprietary technology based on engineering a naturally occurring class of transcription factors known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs so that they can selectively bind to and regulate a target gene, the Company has created ZFP transcription factors that can control gene expression and, consequently, cell function. The Company intends to establish Universal Gene Recognition as a broadly used technology platform for commercial applications in pharmaceutical discovery, human therapeutics, DNA diagnostics and agricultural and industrial biotechnology.
More from Market Guide: Expanded Business Description

Financial Summary
Sangamo Biosciences, Inc. is engaged in the research and development of novel transcription factors for the regulation of gene expression. For the six months ended 6/30/01, total revenues increased 28% to $2 million. Net loss applicable to Common fell 25% to $4.5 million. Revenues reflect the new Universal Genetools agreement income. Lower loss was partially offset by $1.5 million preferred dividend and higher research expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Edward Lanphier II, 44
Pres, CEO, Director
$448K--  
Peter Bluford, 46
VP, Corp. Devel.
186K$750K
Casey Case, Ph.D., 45
VP, Research
191K32K
Shawn Johnson, 33
Director of Fin.
--  --  
Eric Rhodes, 40
Director of Commercial Devel.
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:SGMOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 5-Apr-2001
$6.625
Recent Price$10.00 
52-Week High
on 1-Sep-2000
$51.375
Daily Volume (3-month avg)97.5K
Daily Volume (10-day avg)104.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-79.8%
52-Week Change
relative to S&P500
-73.0%
Share-Related Items
Market Capitalization$222.9M
Shares Outstanding22.3M
Float6.00M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.89 
Earnings (ttm)-$0.42 
Earnings (mrq)-$0.11 
Sales (ttm)$0.18 
Cash (mrq)$2.68 
Valuation Ratios
Price/Book (mrq)3.46 
Price/EarningsN/A 
Price/Sales (ttm)56.37 
Income Statements
Sales (ttm)$3.86M
EBITDA (ttm)-$13.7M
Income available to common (ttm)-$9.10M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-13.33%
Return on Equity (ttm)-13.62%
Financial Strength
Current Ratio (mrq)55.31 
Debt/Equity (mrq)0 
Total Cash (mrq)$59.8M
Short Interest
As of 8-Aug-2001
Shares Short1.01M
Percent of Float16.9%
Shares Short
(Prior Month)
870.0K
Short Ratio15.86 
Daily Volume64.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.